Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clobetasol propionate + regorafenib
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Topical, Oral
01
Overview
Clobetasol propionate + regorafenib is a combination of two pharmaceutical agents used together primarily to manage and prevent hand-foot skin reaction (HFSR), a common adverse effect associated with regorafenib therapy in cancer patients. Clobetasol propionate is a high-potency topical corticosteroid that exerts anti-inflammatory, immunosuppressive, and antimitotic effects by modulating cytokine production and cellular function in the skin. Regorafenib is an oral multikinase inhibitor targeting several protein kinases involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment. The combination does not represent a fixed-dose product but rather concurrent use of both drugs as part of supportive care protocols for patients receiving regorafenib for cancers such as metastatic colorectal cancer or gastrointestinal stromal tumors[2][4][7][9].
- Brand names
- ClobexTemovateImpoyz
- Other names
- clobetasol topicalclobetasol creamregorafenib oral
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FGFR1 (Fibroblast growth factor receptor 1)GR (Glucocorticoid receptor)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR (FGFR family)
Beyond the preview
Go deeper on clobetasol propionate + regorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clobetasol propionate + regorafenib.